Operating cash flow of $86.5M in 2026Q3 against net income of $21.8M, with capital expenditures under 0.4% of revenue, suggests strong cash conversion, although free cash flow margins swung between -5.8% and 59.6% across periods, pointing to working-capital timing effects.
Collegium Pharmaceutical, Inc. (COLL) cash flow statement — 13-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Cash from Operations | 338.02M | 329.32M | 204.98M | 274.75M | 124.23M | 103.56M | 93.94M | 27.78M | 169.39M | -67.02M | -75.05M | -21.57M | -17.95M | -16.53M |
| Operating CF Margin % | - | 42.19% | 32.46% | 48.48% | 26.78% | 37.4% | 30.3% | 9.36% | 60.41% | -235.35% | -4386.5% | - | - | - |
| Operating CF Growth % | 57.25% | 60.66% | -25.39% | 121.16% | 19.96% | 10.23% | 238.13% | -83.6% | 352.75% | 10.71% | -248% | -20.17% | -8.57% | - |
| Net Income | 38.17M | 62.87M | 69.19M | 48.16M | -25M | 71.52M | 26.75M | -22.72M | -39.13M | -74.86M | -94.18M | -27.25M | -17.92M | -16.2M |
| Depreciation & Amortization | 232.82M | 226.07M | 169.16M | 149.26M | 138.94M | 68.92M | 61.55M | 15.48M | 110.91M | 594K | 655K | 171K | 187K | 169K |
| Stock-Based Compensation | 47.56M | 41.91M | 32.4M | 27.14M | 22.87M | 24.25M | 21.91M | 16.53M | 13.78M | 7.95M | 5.79M | 2.21M | 22K | 62K |
| Deferred Taxes | -44.67M | -25.66M | -26.81M | -2.15M | -8.39M | -78.04M | 0 | 0 | 0 | 1.84M | 0 | 0 | 0 | 79K |
| Other Non-Cash Items | 15.02M | 20.37M | 16.02M | 30.62M | 8.52M | 3.42M | 9.03M | -5.59M | 19.28M | -34K | -34K | -28K | -20K | -9K |
| Working Capital Changes | 49.12M | 3.76M | -54.98M | 21.73M | -12.71M | 13.49M | -25.3M | 24.08M | 64.55M | -2.5M | 12.71M | 3.34M | -219K | -634K |
| Change in Receivables | -18.25M | 17.2M | -4.41M | 3.59M | -21.78M | -22.52M | -10.37M | 4.99M | -68.23M | -7.84M | -2.13M | 0 | 0 | 0 |
| Change in Inventory | 11.19M | -5.35M | 13.93M | 14.17M | 48.27M | -2.3M | -8.27M | -1.83M | 219K | -497K | -1.32M | 0 | 0 | 0 |
| Change in Payables | 356K | 6.72M | -11.28M | 5.06M | -707K | -5.83M | 3.77M | 0 | 6.46M | -3.42M | 5.57M | 1.3M | 990K | -822K |
| Cash from Investing | -521.31M | -63.53M | -287.76M | -70.81M | -573.69M | -1.94M | -373.77M | -6.44M | -24.35M | -990K | -2.98M | -362K | -8K | -206K |
| Capital Expenditures | -1.73M | -1.74M | -1.65M | -461K | -1.62M | -1.94M | -5.55M | -6.44M | -24.35M | -990K | -2.98M | -362K | -8K | -206K |
| CapEx % of Revenue | 0.21% | 0.22% | 0.26% | 0.08% | 0.35% | 0.7% | 1.79% | 2.17% | 8.69% | 3.48% | 173.99% | - | - | - |
| Acquisitions | -655.4M | 0 | -267.54M | 0 | -572.07M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | -368.23M | 0 | -18.88M | 0 | -2.5M | 0 | 0 | 0 |
| Cash from Financing | 178M | -110.25M | -60.6M | -140.18M | 436.72M | -89.3M | 286.47M | 2.04M | -117.2M | 33.48M | 135.56M | 115.99M | 12.04M | 12.35M |
| Debt Issued (Net) | 251.8M | -70.38M | 7.52M | -65.92M | 442.68M | -50M | 281.39M | 0 | 10.02M | -2.67M | -2.67M | -1.34M | 11.97M | 395K |
| Equity Issued (Net) | -45.87M | -19.46M | -60.02M | -75M | -14.06M | -47.86M | 0 | -822K | -30K | 34.34M | 137.34M | 116.84M | 0 | 11.96M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -24.57M | -24.57M | 0 | 0 |
| Share Repurchases | -50M | -25.1M | -60.02M | -75M | -14.06M | -47.86M | 0 | -822K | -560K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -27.94M | -20.4M | -8.1M | 740K | 8.1M | 8.56M | 5.08M | 2.86M | -127.19M | 1.81M | 885K | 25.07M | 72K | 1K |
| Net Change in Cash | -5.29M | 155.55M | -143.38M | 63.76M | -12.74M | 12.31M | 6.64M | 23.39M | 27.84M | -34.53M | 57.53M | 94.06M | -5.92M | -4.38M |
| Free Cash Flow | 336.29M | 327.58M | 203.33M | 274.29M | 122.61M | 101.61M | -279.83M | 21.34M | 145.04M | -68.01M | -78.03M | -21.93M | -17.95M | -16.74M |
| FCF Margin % | 41.25% | 41.97% | 32.2% | 48.4% | 26.43% | 36.7% | -90.26% | 7.19% | 51.72% | -238.83% | -4560.49% | - | - | - |
| FCF Growth % | 16.24% | 61.11% | -25.87% | 123.71% | 20.66% | 136.31% | -1410.99% | -85.28% | 313.26% | 12.84% | -255.83% | -22.13% | -7.28% | - |
| FCF per Share | 8.60 | 8.25 | 5.03 | 6.56 | 3.62 | 2.48 | -7.96 | 0.64 | 4.40 | -2.25 | -3.22 | -1.62 | -2.40 | -2.24 |
| FCF Conversion (FCF/Net Income) | 8.81x | 5.24x | 2.96x | 5.71x | -4.97x | 1.45x | 3.51x | -1.22x | -4.33x | 0.90x | 0.80x | 0.79x | 1.00x | 1.02x |
| Interest Paid | 72.47M | 68.76M | 62.43M | 73.26M | 52.53M | 17.61M | 18.97M | 709K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 50.16M | 60.04M | 52.09M | 24.2M | 10.4M | 3M | 483K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying COLL stock.
Collegium Pharmaceutical, Inc. (COLL) generated $329.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Collegium Pharmaceutical, Inc. (COLL) generated $327.6M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Collegium Pharmaceutical, Inc. (COLL) spent $1.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Collegium Pharmaceutical, Inc. (COLL) spent $25.1M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Leverage limits revenue shortfall tolerance
Metrics are mathematically derived from official filings.
Operating Cash Flow Far Exceeds Volatile Earnings
According to reported quarterly figures, COLL generated operating cash flow of $86.5M in 2026Q3 against net income of just $21.8M, while 2026Q2 net loss of $15.1M still produced $71.3M of operating cash flow, pointing to heavy non-cash charges.
The gap between net income and operating cash flow is the dominant signal in this dataset, with OCF/NI ratios swinging from -4.74 to 3.98 and from 22.92 in 2025Q1 to 2.49 in 2025Q3. This pattern suggests reported earnings are dominated by amortization of acquired intangibles and accrual timing rather than by the cash economics of the business. Investors should monitor whether the cash generation proves durable once working capital and rebate accrual swings normalize, since the quarterly noise makes earnings a poor standalone proxy for cash power.
Free Cash Flow Margins Swing With Working Capital
Based on reported figures, COLL's free cash flow margin ranged from -5.8% in 2024Q3 to 59.6% in 2025Q4, with a 2026Q3 margin of 39.9%, indicating that quarterly FCF is driven more by working capital timing than by a steady operating trend.
Capital expenditure is negligible, running below 0.5% of revenue in every period, so FCF tracks operating cash flow almost one-for-one. The sharp working capital reversals, including a $64.0M outflow in 2024Q3 and a $33.8M inflow in 2025Q4, appear to explain most of the margin volatility. The trailing trend is encouraging, but a single-quarter read is not sufficient to establish a sustainable margin level.
Capital Intensity Is Negligible Across Periods
As reported in financial statements, COLL's capital expenditures stayed between $65K and $798K per quarter, equal to roughly 0.0% to 0.4% of revenue, implying an asset-light cash profile that depends on amortization rather than reinvestment.
Depreciation and amortization of roughly $55M to $57M per quarter far exceeds capital spending, which indicates that the non-cash charge is driven almost entirely by acquired intangible assets rather than productive equipment. This makes the D&A add-back the largest reconciling item between net income and cash flow. Investors should recognize that low capex flatters free cash flow, while the amortization burden reflects the price paid for past acquisitions.
Buybacks Intermittent, Acquisitions Dominate Outflows
Based on reported figures, COLL deployed $655.4M into acquisitions in 2026Q2 while paying no dividends in any period and making buybacks of $25.0M to $50.0M in only four of ten quarters, suggesting cash is directed toward portfolio expansion rather than shareholder returns.
The 2026Q2 acquisition outflow exceeds that quarter's operating cash flow by roughly nine times, implying the purchase was financed through debt or balance sheet resources rather than internal cash generation. Given the reported debt-to-equity ratio of 3.12, this sequencing warrants further investigation into how the acquisition was funded. Repurchases appear opportunistic rather than systematic, consistent with management prioritizing deleveraging and portfolio diversification.
Cumulative Cash Outpaces Reported Earnings
Across the ten reported quarters, COLL's cumulative operating cash flow of roughly $636M compares with cumulative net income of roughly $117M, indicating that accrual-based earnings have materially understated cash generation over this window.
The cumulative gap of more than five times between operating cash flow and net income is unusually wide and suggests that non-cash amortization and accrual dynamics dominate reported profitability. This divergence means that GAAP earnings may understate the economic cash contribution of the franchise. Investors should view the gap as a reason to examine the sustainability of the amortization base rather than as proof of earnings quality.
Cash Strength May Mask Leverage Exposure
Based on reported figures, COLL's strong quarterly operating cash flow coexists with a debt-to-equity ratio of 3.12 and a net margin of 8.1%, suggesting that cash generation may overstate financial flexibility if revenue growth stalls further.
The cash flow profile is dominated by non-cash amortization add-backs, so the headline OCF figures may not translate fully into discretionary capacity once debt service and acquisition commitments are considered. The 2026Q2 acquisition outflow of $655.4M raises questions about the balance sheet cost of that transaction that the provided data does not fully resolve. Investors should monitor whether operating cash flow remains durable after normalizing for working capital swings and whether opioid-related production quota constraints affect the cash base.